Status:
COMPLETED
The Vienna Prograf and Endothelial Progenitor Cell Extension Study
Lead Sponsor:
Medical University of Vienna
Conditions:
Immunosuppression
Renal Failure
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Conversion of renal transplant recipients from either tacrolimus or cyclosporin A to tacrolimus modified release to investigate the effects of the MDR1/CYP450 genotype on the trough blood levels of ta...
Detailed Description
The study concerns the conversion of immunosuppressive agents among participants in the clinical trial "The Vienna Prograf and Endothelial Progenitor Cell Study - The Vienna PEP Study" at the end of t...
Eligibility Criteria
Inclusion
- Any stable long-term kidney transplant recipient who participated in the Vienna Prograf and Endothelial-Progenitor Study (Vienna PEP Study; EudraCT identifier 2004-82 004209-98)
- Written informed consent to have the immunosuppression converted from either cyclosporin A or tacrolimus to tacrolimus modified-release
Exclusion
- Graft failure
- Contraindication to receive immunosuppression
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT03751332
Start Date
March 1 2008
End Date
October 1 2010
Last Update
November 23 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.